Charles River Laboratories Partners With FOXG1 Research Foundation To Advance AAV9 Gene Therapy Clinical Trials; Collaboration Leverages Plasmid And Viral Vector CDMO Expertise To Drive Drug Development For FOXG1 Syndrome And Related Neurological Disorders
Portfolio Pulse from Benzinga Newsdesk
Charles River Laboratories has partnered with the FOXG1 Research Foundation to advance AAV9 gene therapy clinical trials. This collaboration leverages Charles River's expertise in plasmid and viral vector CDMO to drive drug development for FOXG1 Syndrome and related neurological disorders.
July 30, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Charles River Laboratories has entered into a partnership with the FOXG1 Research Foundation to advance AAV9 gene therapy clinical trials. This collaboration utilizes Charles River's expertise in plasmid and viral vector CDMO, potentially accelerating drug development for FOXG1 Syndrome and related neurological disorders.
The partnership with the FOXG1 Research Foundation is likely to positively impact Charles River Laboratories by enhancing its role in the gene therapy space. Leveraging their CDMO expertise could lead to accelerated drug development, which is a significant growth area in biotechnology.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100